Lybrido was the first product we developed for the treatment of FSIAD. It proved effective for women with low sex drive and motivation as a result of insensitivity to sexual cues.
Lybrido increases central sexual motivation and physiological sexual response, such as swelling of vaginal erectile tissue and lubrication.
However, in our studies we found that Lybrido was not effective in the subgroup of women who suffer from FSIAD as a result of inhibitory mechanisms. We assumed that these women can be aroused, but that negative associations with sex trigger an inhibitory reflex in the brain. This can be the result of past experiences.
For the effective treatment of this second group, we subsequently developed Lybridos.